FDA Brief

Warning letters Biologics

FDA warning letter to

Tides Medical LLC

High riskIssued Oct 6Posted Oct 20Center for Biologics Evaluation and Research (CBER)

FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

What happened

FDA reviewed Tides Medical's website for APLICOR 3D, last visited in October 2026, and records; it says the firm distributes the device in the U.S. without marketing clearance or approval. FDA says APLICOR 3D is adulterated because no approved premarket approval (PMA) or investigational device exemption (IDE) is in effect, and misbranded because the firm did not submit the required 510(k) premarket notification. The letter also says the firm claimed a Class I liquid medication dispenser exemption, but the product's stated wound-care uses exceed that exemption.

What FDA found

  1. FDA says APLICOR 3D is adulterated because there is no approved PMA or IDE for the device.

    section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  2. FDA says APLICOR 3D is misbranded because the firm did not timely notify FDA before commercial distribution.

    section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)
  3. FDA says the firm's Class I liquid medication dispenser exemption does not apply because APLICOR 3D is intended for wound-care uses different from that classification.

    21 CFR 880.6430; 21 CFR 880.9

What FDA wants

FDA requests that Tides Medical stop activities that make APLICOR 3D illegally marketed, including commercial distribution for the stated uses. The firm must respond in writing within 15 business days with corrective actions or its reasoning and supporting information.

Who should pay attention

  • wound care clinics and providers offered APLICOR 3D
  • distributors of unapproved wound-care devices
  • companies relying on Class I exemptions for devices with expanded uses

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Specialty Health Products CO, LLC

    Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

    High risk